GERN
Geron Corporation
$1.28
$0.00(0.00%)
40
Overall
60
Value
20
Tech
42
Quality
Market Cap
$695.81M
Volume
10.58M
52W Range
$1.04 - $2.01
Target Price
$3.40
Company Overview
| Mkt Cap | $695.81M | Price | $1.28 |
| Volume | 10.58M | Change | +0.00% |
| P/E Ratio | -8.3 | Open | $1.30 |
| Revenue | -- | Prev Close | $1.28 |
| Net Income | $-83.5M | 52W Range | $1.04 - $2.01 |
| Div Yield | N/A | Target | $3.40 |
| Overall | 40 | Value | 60 |
| Quality | 42 | Technical | 20 |
No chart data available
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Latest News
Geron Earnings Call Highlights Growth, Pricing Pressures
TipRanks Auto-Generated Newsdesk•7 days ago
Needham Remains a Buy on Geron (GERN)
TipRanks Auto-Generated Intelligence Newsdesk•20 days ago
Analysts Are Bullish on These Healthcare Stocks: Geron (GERN), Regeneron (REGN)
Catie Powers•20 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GERN | $1.28 | 0% | 10.58M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |